Skip to main content
RAPS Euro Convergence 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed Event
Ticketed Event
Sponsored Presentation
Sponsored Presentation
Learning Level: Foundational
Learning Level: Foundational
New Exhibitor
New Exhibitor
Networking Event
Networking Event
Enterprise Network Member
Enterprise Network Member
Learning Level: Expert
Learning Level: Expert
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Intermediate
Learning Level: Intermediate
Back

Dhriti Roy, PhD

Vice President of Regulatory Affairs Transformation
Essenvia

Dr. Dhriti Roy is the Vice President of Regulatory Affairs Transformation at Essenvia, who has over 20 years of experience as a regulatory affairs executive and digital transformation expert across various industries such as medical devices, in vitro diagnostics, pharmaceuticals, biologics, and consumer products. Dr. Roy has demonstrated successful leadership and expertise in the execution of quality, regulatory, and clinical strategies for market-leading companies like Abbott, Medtronic, Zoll, Danahar, and Labcorp, as well as early-stage organizations.

She assists manufacturers in submitting IDEs, PMA, and 510 (K) for Class I to Class III devices. Dr. Roy specializes in FDA regulatory compliance, EU MDR and IVDR transition, SaMD and SiMD device regulations in cardiovascular, radiology, critical care, organ perfusion systems, and more. Notably, she has led worldwide regulatory efforts on the buy and sell side for M&A deals ranging from $100 million to more than $5 billion in individual value.

Dr. Roy holds a doctorate in environmental engineering and an MBA from the University of Oxford. She is also a leading scientist and has contributed to highly-ranked scientific research publications. As a faculty at Oxford University, she mentors Innovations and market access in the medical technologies sector. Additionally, she serves as a board member and investor for a venture capital firm focused on impact investment funds for early-stage ventures in the health technology sector.

Disclosure information not submitted.

Presentation(s):